Researchers study effects of Aricept in pediatric brain cancer survivorsNovember 06, 2006WINSTON-SALEM, N.C. - A pediatric oncologist at Brenner Children's Hospital is evaluating whether a drug typically used to treat Alzheimer's patients will help brain cancer survivors avoid the learning and memory problems that are common after radiation therapy. The drug, called AriceptTM, will be given daily for six months to brain cancer survivors who have received cranial radiation. Sharon Castellino, M.D., will follow these patients for six months to see if the drug can help prevent a decline in their cognitive abilities. The Comprehensive Cancer Center at Wake Forest Baptist completed a successful pilot study using this drug in adults last year. The researchers decided to try the drug after observing that radiation-induced brain injury resembles Alzheimer's disease and other forms of dementia not only in the clinical symptoms but also in what is seen with brain imaging, "We know that pediatric brain cancer patients are at risk for developing cognitive problems later in life," said Castellino. "They may have memory problems, low school performance, declines in IQ, behavioral problems, and these problems may lead to poor quality of life. Patients who receive cranial radiation as part of their treatment regime are at greater risk for developing these problems. We are hoping this therapy will enable them to maintain their baseline cognitive abilities and social relationships at school and at home." Castellino and colleagues will enroll 35 patients, ages 8 to 17 years, in this study over the next two years. Patients will be asked to take a series of neuropsychological tests to establish a baseline of their cognitive abilities before starting treatment. Patients must have completed all therapy at least one year ago. Brenner Children's Hospital treats about 20 pediatric patients with brain tumors each year. Over two-third of patients who are diagnosed with a malignant brain tumor will receive cranial radiation, she said. "Cranial radiation can be particularly damaging to the brain if the treatment area is large," Castellino said. "The age of the child also plays a significant role in developing cognitive problems. Radiation therapy can stunt the normal development of a child's brain." Wake Forest University Baptist Medical Center |
|||||||||||||||||||||
| Related Brain Cancer Current Events and Brain Cancer News Articles Magnetic nanoparticles to simultaneously diagnose, monitor and treat Whether it's magnetic nanoparticles (mNPs) giving an army of 'therapeutically armed' white blood cells direction to invade a deadly tumour's territory, or the use of mNPs to target specific nerve channels and induce nerve-led behaviour (such as the life-dependant thumping of our hearts), mNPs have come a long way in the past decade. Angiochem crosses BBB, shows safety, efficacy in phase 1/2 brain cancer studies Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases. Toward a nanomedicine for brain cancer In an advance toward better treatments for the most serious form of brain cancer, scientists in Illinois are reporting development of the first nanoparticles that seek out and destroy brain cancer cells without damaging nearby healthy cells. UM scientists pinpoint critical molecule to celiac disease, possibly other autoimmune disorders It was nine years ago that University of Maryland School of Medicine researchers discovered that a mysterious human protein called zonulin played a critical role in celiac disease and other autoimmune disorders, such as multiple sclerosis and diabetes. Experts warn over health check brain scans A new study has voiced concern about the growing market for brain screening tests, which people can buy as part of a general health MOT. Avastin dramatically improves response, survival in deadly recurrrent glioblastomas The targeted therapy Avastin, alone and in combination with the chemotherapy drug CPT-11, significantly increased response rates, progression-free survival times and survival rates in patients with a deadly form of brain cancer that had recurred. Computational Process Zeroes in on Top Genetic Cancer Suspects Johns Hopkins engineers have devised innovative computer software that can sift through hundreds of genetic mutations and highlight the DNA changes that are most likely to promote cancer. NIH study reveals new genetic culprit in deadly skin cancer Drawing on the power of DNA sequencing, National Institutes of Health researchers have identified a new group of genetic mutations involved in the deadliest form of skin cancer, melanoma. NIH researchers identify key factor that stimulates brain cancer cells to spread Researchers funded by the National Institutes of Health have found that the activity of a protein in brain cells helps stimulate the spread of an aggressive brain cancer called glioblastoma multiforme (GBM). Anti-psychotic drugs could help fight cancer The observation that people taking medication for schizophrenia have lower cancer rates than other people has prompted new research revealing that anti-psychotic drugs could help treat some major cancers. More Brain Cancer Current Events and Brain Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||